^
    CANCER:

    Thyroid Gland Papillary Carcinoma





    Show legend
    Group by Gene:
    Include preclinical:

    0
    Multi-tyrosine kinase inhibitor
    cabozantinib tablet
    cabozantinib capsule
    1
    TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor
    larotrectinib
    2
    RANK ligand inhibitor
    denosumab
    3
    BRAF inhibitor, BRAF V600E inhibitor
    vemurafenib
    FORE-8394
    4
    MEK inhibitor, BRAF inhibitor
    trametinib + dabrafenib
    BRAF inhibitor + MEK inhibitor
    5
    RET inhibitor
    selpercatinib
    pralsetinib
    6
    PD1 inhibitor
    pembrolizumab
    7
    BRAF inhibitor
    dabrafenib
    8
    IL-6 inhibitor
    siltuximab
    9
    TrkB receptor inhibitor, TrkC kinase inhibitor, ROS1 inhibitor, TrkA receptor antagonist
    AB-106
    10
    FGFR inhibitor, VEGFR inhibitor, RET inhibitor, c-KIT inhibitor, PDGFR α antagonist
    lenvatinib
    11
    pan-RAF inhibitor, Multi-tyrosine kinase inhibitor
    sorafenib
    12
    TrkB receptor inhibitor, TrkC kinase inhibitor, ROS1 inhibitor, TrkA receptor inhibitor, ALK inhibitor, JAK2 inhibitor, TNK2 inhibitor
    entrectinib
    13
    BRAF inhibitor, MEK1 inhibitor, BRAF V600E inhibitor
    vemurafenib + cobimetinib
    14
    pan-RAF inhibitor, EGFR inhibitor
    BGB-283
    15
    BRAF inhibitor, BRAF V600E inhibitor, Cytochrome P450 inhibitor
    FORE-8394 + cobicistat
    16
    MEK inhibitor, BRAF inhibitor, MEK2 inhibitor, MEK1 inhibitor, BRAF V600E inhibitor
    vemurafenib + HL-085
    17
    AKT inhibitor
    MK-2206
    18
    Bcr-abl tyrosine kinase inhibitor, MEK inhibitor, Src kinase inhibitor, c-KIT inhibitor, PDGFR β antagonist, EphA2 receptor antagonist
    dasatinib + CI-1040
    19
    Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, c-KIT inhibitor, PDGFR β antagonist, EphA2 receptor antagonist
    dasatinib
    20
    Aurora kinase inhibitor, MEK inhibitor, SRC-family kinase (SFK) inhibitor
    CI-1040 + SU6656
    21
    MEK inhibitor, Src kinase inhibitor
    CI-1040 + PP2
    22
    MEK inhibitor
    CI-1040
    23
    JAK1 inhibitor, JAK2 inhibitor
    AZD1480
    24
    MEK inhibitor, BRAF inhibitor, WEE1 inhibitor
    trametinib + dabrafenib + AZD1775
    25
    Src kinase inhibitor
    PP2
    No biomarker
    BRAF V600
    BRAF V600E
    BRAF mutation
    RET fusion
    NTRK1 fusion
    NTRK1 overexpression
    RET rearrangement
    RET C634W
    RET M918T
    TMB-H
    NCOA4-RET fusion
    NTRK3 fusion
    GLI3 overexpression
    GLI2 overexpression
    GLI1 overexpression
    TPM3-NTRK1 fusion
    EGFR overexpression
    NTRK2 fusion
    NRAS Q61K + BRAF V600E
    PDGFRB overexpression
    MSI-H/dMMR
    RET-PTC1 rearrangement
    BRAF V600E + TERT mutation
    PTEN R130del
    PIK3CA E545K